Glenmark Pharmaceuticals Ltd Quarterly Results
Q1 FY26-27 Results Summary
Revenue
The revenue stands at ₹4,018.48 crore, reflecting a quarter-on-quarter *(QoQ) increase of 6.57 per cent from ₹3,770.59 crore. This corresponds to a year-on-year *(YoY) growth of 23.10 per cent.
Operating Profit
Operating Profit stands at ₹804.79 crore, reflecting a quarter-on-quarter *(QoQ) increase of 106.78 per cent from ₹389.20 crore. This corresponds to a year-on-year *(YoY) growth of 212.79 per cent.
PBDT
PBDT stands at ₹816.55 crore, reflecting a quarter-on-quarter *(QoQ) increase of 52.44 per cent from ₹535.67 crore. This corresponds to a year-on-year *(YoY) growth of 262.11 per cent.
Profit Before Tax
Profit Before Tax stands at ₹643.38 crore, reflecting a quarter-on-quarter *(QoQ) increase of 65.92 per cent from ₹387.76 crore. This corresponds to a year-on-year *(YoY) growth of 573.20 per cent.
Net Profit
Net Profit stands at ₹482.82 crore, reflecting a quarter-on-quarter *(QoQ) increase of 60.24 per cent from ₹301.31 crore. This represents a 927.93 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Glenmark Pharmaceuticals Ltd News
Glenmark Pharmaceuticals Ltd Earnings
- YOY
- QOQ
Glenmark Pharmaceuticals Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Glenmark Pharmaceuticals Ltd Research Reports
Glenmark Pharmaceuticals Ltd Financial Reports
Glenmark Pharmaceuticals Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Glenmark Pharma. | -2.45% | -3.68% | -4.05% | -9.98% | 10.45% | 6.20% |
| Aurobindo Pharma | 0.74% | 0.01% | -0.18% | 11.40% | 34.55% | 47.31% |
| Biocon | -0.62% | -1.82% | -0.39% | 14.67% | 15.04% | 13.54% |
| Alkem Lab | -1.21% | 0.17% | 1.53% | 5.14% | 0.37% | 15.57% |
| Abbott India | -0.08% | 0.15% | 3.39% | 9.63% | 1.93% | -16.54% |
| Anthem Bioscienc | 2.69% | 5.18% | 7.27% | 9.15% | 30.66% | 12.85% |
| Glaxosmi. Pharma | 0.57% | 1.57% | 11.16% | 12.96% | 9.23% | -6.05% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : Glenn Saldanha
ED / WTD / Promoter : Cheryl Pinto
ED / President / Global CFO : Anurag Mantri
Non Executive Director : B E Saldanha
Independent Non Exe. Director : Sona Saira Ramasastry
Independent Non Exe. Director : Dipankar Bhattacharjee
Independent Non Exe. Director : V R Iyer
Independent Non Exe. Director : Pradeep Kumar Sinha
Company Sec. & Compli. Officer : Harish Kuber